Drug intelligence / Profile preview

technetium-99m labelled photosensitizer-peptide conjugate

Development stage
Preclinical
Lead developer
University of Vienna
Modality
Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Gamma Emitters → Radiopharmaceuticals, Peptide-Drug Conjugates → Peptide Conjugates → Peptides
Administration
Intravenous
01

Overview

Technetium-99m labelled photosensitizer-peptide conjugate is a preclinical-stage theranostic radiopharmaceutical developed for cancer imaging and therapy. The agent is a peptide-drug conjugate consisting of a targeting peptide that binds to the gastrin-releasing peptide receptor (GRPR), conjugated to a ruthenium(II)-based photosensitizer (Ru-PS) and radiolabeled with technetium-99m. This bimodal design allows for single-photon emission computed tomography (SPECT) imaging to track the agent in vivo, combined with photodynamic therapy (PDT) to induce localized phototoxicity upon light irradiation. The platform also offers potential for radionuclide therapy by exchanging the diagnostic technetium-99m isotope with therapeutic rhenium-188.

Other names
99mTc-labelled PS-peptide conjugate99mTc-labelled Ru-based photosensitizer-peptide conjugatetechnetium-99m labelled Ru-based photosensitizer-peptide conjugatetechnetium99m labelled Ru-based photosensitizer-peptide conjugatetechnetium 99m labelled Ru-based photosensitizer-peptide conjugate
02

Identity

Drug type
Peptides
Modality
Peptide-Drug ConjugatesAntibody-Based TherapeuticsAntibody-Radionuclide ConjugatesGamma Emitters
03

Pharmacology

Route
Intravenous
04

Regulatory

MarketStatusYear
United StatesNot approved—
European UnionNot approved—
ChinaNot approved—
JapanNot approved—

Approved indications and other markets are in the full profile.

05

Companies

  • University of ViennaLead developer
06

Competitive landscape

Drugs on the same target
25

Most advanced

  1. [68Ga]-LNTH-2401Phase 3
  2. 68Ga-DOTA-BombesinPhase 3
  3. 177Lu-NeoBPhase 2
  4. 68Ga-G23Phase 2
  5. ASP7147Phase 2

Beyond the preview

Go deeper on technetium-99m labelled photosensitizer-peptide conjugate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on technetium-99m labelled photosensitizer-peptide conjugate.

Work on technetium-99m labelled photosensitizer-peptide conjugate? Claim this page to correct or add information. Claim this page

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call